Semaglutide vs Tirzepatide: Which Works Better for Weight Loss?

Editorial correction: This article previously stated that no large head-to-head weight-loss trial existed. The SURMOUNT-5 evidence below corrects that statement. This update is awaiting medical review.

Semaglutide vs Tirzepatide: Which Works Better for Weight Loss?

The conversation around weight management has changed dramatically in recent years, largely due to a new class of powerful medications. Two of the most talked-about names are semaglutide and tirzepatide. If you're exploring your options, you might be wondering: what’s the difference, and which one is more effective for weight loss?

This article offers a practical, evidence-aware guide to help you understand these two medications. We'll compare how they work, what clinical trials have shown, and their common side effects, so you can have a more informed discussion with your doctor. Consult your healthcare provider before starting any medication.

What is Semaglutide?

Semaglutide is a medication that belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. That’s a mouthful, but the concept is fairly simple. It works by mimicking a natural gut hormone, GLP-1, that our bodies release after we eat.

This hormone sends signals to the brain that you’re full, slows down how quickly your stomach empties, and helps regulate blood sugar. By activating these same pathways, semaglutide helps reduce appetite and calorie intake, which can lead to significant weight loss.

Semaglutide is the active ingredient in medications approved for type 2 diabetes (Ozempic, Rybelsus) and for chronic weight management (Wegovy).

What is Tirzepatide?

Tirzepatide is a newer medication that takes a slightly different approach. It’s the first in its class, known as a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist.

Like semaglutide, it mimics the GLP-1 hormone. However, it also mimics a second gut hormone called GIP. This dual-action mechanism targets two distinct pathways involved in appetite regulation and metabolism. Clinical trials compare the medicines’ outcomes; they do not establish how much of the difference is attributable to each receptor.

Tirzepatide is the active ingredient in medications approved for type 2 diabetes (Mounjaro) and for chronic weight management (Zepbound).

Brand names, approved indications and available doses vary by country; the brand examples here refer to U.S. approvals.

Head-to-Head: A Look at the Key Differences

This comparison focuses on the once-weekly injectable regimens studied for weight loss. Semaglutide also has oral formulations; the findings below should not be assumed to apply to every formulation or dose.

Mechanism of Action: One Target vs. Two

The fundamental difference lies in their biology.

• Semaglutide is a single-agonist medication, targeting only the GLP-1 receptor.
• Tirzepatide is a dual-agonist medication, targeting both the GLP-1 and GIP receptors.

The receptor targets differ, but treatment outcomes must be assessed from clinical evidence rather than inferred from the number of targets.

Weight Loss Efficacy: What the Studies Show

This is the question on most people’s minds: which one leads to more weight loss? Clinical trials provide the clearest picture.

STEP 1 studied once-weekly semaglutide 2.4 mg in adults with obesity, or overweight with a weight-related condition, without diabetes. At 68 weeks, estimated mean weight change was −14.9% with semaglutide versus −2.4% with placebo; both groups received lifestyle intervention. Read the STEP 1 study.

For tirzepatide, the SURMOUNT-1 trial, also published in The New England Journal of Medicine, evaluated its use for weight management. After 72 weeks, participants on the highest dose (15 mg) lost an average of 20.9% of their initial body weight, compared to 3.1% for the placebo group.

These placebo-controlled trials provide background, but comparing their results across separate studies is not a head-to-head comparison.

Direct evidence is available from SURMOUNT-5, published online in The New England Journal of Medicine on May 11, 2025. This randomized, open-label Phase 3b trial enrolled 751 adults with obesity, or overweight with at least one weight-related condition, without diabetes. It compared maximum-tolerated once-weekly doses of tirzepatide (10 or 15 mg) with semaglutide (1.7 or 2.4 mg).

At 72 weeks, the estimated mean reduction in body weight was 20.2% with tirzepatide versus 13.7% with semaglutide. Tirzepatide produced greater average weight loss in this trial. The study was funded by Eli Lilly. Read the original SURMOUNT-5 abstract.

These results apply to the population and doses studied. They do not establish the best treatment for every person, compare every formulation or dose, or guarantee an individual outcome. Treatment choice also depends on medical history, tolerability, access and a clinician’s assessment.

SURMOUNT-5 did not compare tirzepatide with semaglutide 7.2 mg or oral semaglutide. The FDA approved Wegovy HD 7.2 mg in March 2026, so the trial should not be described as comparing every currently approved dose. FDA approval announcement.

Common Side Effects

Common gastrointestinal side effects of both medicines include nausea, diarrhea, vomiting, constipation and abdominal pain. In SURMOUNT-5, gastrointestinal events were generally mild to moderate and most often occurred during dose escalation. Some people stopped treatment because of adverse effects; the trial was not designed to establish that either medicine is safer. Prescribers increase doses gradually to reduce gastrointestinal side effects. See the SURMOUNT-5 abstract and current prescribing information linked below.

Important Safety Considerations

Both U.S. labels carry a boxed warning about thyroid C-cell tumors seen in rodents; whether this risk occurs in humans is unknown. Both medicines are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2, or a serious allergy to the medicine. Important risks include pancreatitis, gallbladder problems, severe gastrointestinal reactions, dehydration-related kidney injury and hypoglycemia, particularly with insulin or sulfonylureas. Both labels also warn about pulmonary aspiration during general anesthesia or deep sedation, so tell the care team about any planned procedure; the Wegovy label also warns about diabetic retinopathy complications in people with type 2 diabetes. Seek urgent care for severe, persistent abdominal pain (which may spread to the back), signs of a serious allergic reaction, or vomiting that stops you keeping fluids down.

Weight-loss treatment should not be used during pregnancy. Tirzepatide can reduce the effectiveness of oral hormonal contraceptives; its label advises a non-oral method or an added barrier method for four weeks after starting and after each dose increase. This is not a complete safety list; review the current Wegovy prescribing information and Zepbound prescribing information with a clinician.

Making an Informed Decision

Choosing a medication is a significant health decision that should not be made alone. The "better" medication is the one that is right for your unique health profile, medical history, and personal goals.

Your doctor will consider many factors, including your starting weight, any existing health conditions (like heart disease or kidney issues), and what your insurance may cover. At Weight Easy, we believe in empowering you with clear information to support these important conversations. Lifestyle is also a huge piece of the puzzle. These medications are most effective when used as part of a comprehensive plan that includes a balanced diet and regular physical activity.

The journey to sustainable weight management is a partnership between you and your healthcare team. Open communication is key to finding the safest and most effective path forward for you. Consult your healthcare provider before starting any medication.

In summary, both semaglutide and tirzepatide are highly effective tools for weight management. SURMOUNT-5 found greater average weight loss with tirzepatide at the doses studied, but that result alone does not determine the best treatment for an individual. The best choice is always a personal one, made in careful consultation with a trusted medical professional who understands your complete health picture.

Sources

1. Novo Nordisk. Wegovy U.S. prescribing information. Revised June 2026. Current prescribing information
2. Eli Lilly. Zepbound U.S. prescribing information. Revised August 2026. Current prescribing information
3. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384, 989–1002. STEP 1 study
4. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine, 387, 205–216. SURMOUNT-1 abstract
5. Aronne, L. J., et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. The New England Journal of Medicine, 393, 26–36. Published online May 11, 2025. SURMOUNT-5 study; PubMed abstract.
6. U.S. Food and Drug Administration. March 19, 2026. FDA approves higher-dose semaglutide (Wegovy HD)